The emergence of AI, notably in the field of drug discovery, is reshaping the future of medicine
The emergence of artificial intelligence (AI), notably in the field of drug discovery, is reshaping the future of medicine. The pharmaceutical business is undergoing a transformation because of this game-changing technology, which promises to hasten drug development, save costs, and enhance patient outcomes.
Drug discovery has typically been a time-consuming and tedious process, costing billions of dollars and up to ten years to bring a new treatment to market. Yet, the incorporation of AI into this procedure has the potential to significantly shorten this period of time. At a fraction of the time required by a human researcher, AI algorithms are able to examine enormous amounts of data at an unprecedented rate.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
